Clinical Trial Update: Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating retifanlimab in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma and is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Recurrent
• Glioma Recurrent

Drugs mentioned

• Bevacizumab (bevacizumab)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | Phase 2 | Status: RECRUITING